A similar enrichment for signature 3 was found for PALB2 and RAD51C mutations or epigenetic silencing of the BRCA1 or RAD51C promoter, but not for inactivation of other cancer-associated genes, such as CHEK2 and ATM [40]. Here, CHEK2 is linked to cancer.